CSIMarket
 
Kamada Ltd   (NASDAQ: KMDA)
 
Price: $8.2300 $-0.06 -0.724%
Day's High: $8.289999961853027 Week Perf: -4.64 %
Day's Low: $ 8.14 30 Day Perf: 15.27 %
Volume (M): 94,824 52 Wk High: $ 9.35
Volume (M$): $ 0 52 Wk Avg: $7.62
Open: $8.17 52 Wk Low: $6.50



 Market Capitalization (Millions $) 480
 Shares Outstanding (Millions) 58
 Employees 393
 Revenues (TTM) (Millions $) 180
 Net Income (TTM) (Millions $) 20
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Kamada Ltd is a biopharmaceutical company that operates in the fields of plasma-derived proteins and immunoglobulins for various medical conditions. The company has over thirty years of experience in the development and commercialization of innovative therapeutics for patients with rare and chronic diseases.

Founded in 1990, Kamada Ltd is headquartered in Rehovot, Israel, and has additional offices and facilities in the United States, Germany, and the United Kingdom. The company has a global network of distributors and partners, enabling it to market its products to medical professionals worldwide.

Kamada Ltd is dedicated to developing therapeutic products to treat a variety of life-threatening conditions, including bleeding disorders, immunodeficiency diseases, pulmonary arterial hypertension, and other medical conditions that require specific proteins and enzymes for treatment. They offer a comprehensive range of products, including Alpha1- Antitrypsin, Immunoglobulin, Coagulation Factors, and other related products.

The company's flagship product, Glassia, is an FDA-approved Alpha1-Proteinase Inhibitor that is used to treat genetic emphysema, a life-threatening condition that affects the lungs. In addition, Kamada Ltd also offers a range of coagulation factors, which are essential for the effective treatment of Bleeding Disorders.

One of Kamada Ltd's significant strengths is its ability to control the entire manufacturing process, from start to finish, to ensure the highest quality and consistency of its products. The company employs a team of dedicated specialists and scientists who use state-of-the-art scientific equipment and technology to develop and manufacture its products.

In addition to its product development activities, Kamada Ltd also offers research and development services to other pharmaceutical companies. The company has a research and development team that is focused on developing innovative and effective treatments for various medical conditions. The company also operates a clinical trial division that conducts comprehensive clinical trials to test the safety and efficacy of its products.

In conclusion, Kamada Ltd is an innovative and reliable biopharmaceutical company that provides high-quality plasma-derived products and immunoglobulins to patients worldwide. The company's commitment to research and development, quality control, and customer service has enabled it to become a leader in the field of biopharmaceuticals.


   Company Address: 2 Holzman St Rehovot 7670402
   Company Phone Number: 8 9406472   Stock Exchange / Ticker: NASDAQ KMDA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BHC   -4.64%    
BMY   -0.7%    
REGN   -3.55%    
TEVA   -2.38%    
VRTX   -0.56%    
VTRS   -0.18%    
• View Complete Report
   



Dividend

Kamada Ltd. Secures Tax Ruling for Special Dividend, Signaling Continued Commitment to Shareholder Value Amid Promising Growth Trajectory

Published Mon, Mar 24 2025 11:01 AM UTC

In a significant development for both the company and its shareholders, Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a premier player in the biopharmaceutical sector known for its expertise in specialty plasma-derived products for rare and serious medical conditions, has announced the acquisition of a tax ruling from the Israel Tax Authority (ITA) pertaining to an upcoming cas...

Management Announcement

Kamada Projects Continued Profitable Growth Ahead: 2024 Financial Guidance and Ambitious Plans for 2025,

Published Wed, Jan 8 2025 12:00 PM UTC

Kamada Projects Continued Profitable Growth Ahead: 2024 Financial Guidance and Ambitious Plans for 2025 Kamada Projects Continued Profitable Growth Ahead: 2024 Financial Guidance and Ambitious Plans for 2025Kamada Ltd. a biopharmaceutical powerhouse hailing from Rehovot, Israel, has set strong financial expectations for 2024, while revealing an optimistic outlook for 2025. A...

Announcement

Kamada Ltd to Unveil Q1 2024 Financial Results Prior to Market Commencement on May 8: A Keenly Awaited Disclosure Reflecting Industry R&D Health

Published Wed, May 1 2024 11:00 AM UTC

Kamada Ltd., a frontrunning global biopharmaceutical firm with a robust portfolio of approved products designed to mitigate the effects of rare and serious conditions, has announced that it will publicize its financial results for the first quarter ending March 31, 2024. As per their statement, the company will release results before the U.S. financial markets begin their tr...

Management Announcement

Kamada Ltd.'s Road to Recovery: Facing Financial Challenges and Outlining a Path Forward.

Published Wed, Mar 6 2024 12:05 PM UTC


In a recent letter to shareholders, Kamada Ltd., a global biopharmaceutical company based in Rehovot, Israel, and Hoboken, N.J., addressed the company s financial performance and its future outlook. Amir London, the Chief Executive Officer, discussed the challenges faced by the company and outlined its plans moving forward.
One of the key points highlighted in the l...

Contract

Kamada Unlocks $180 Million Revenue Potential Through Pivotal KEDRAB Distribution Agreement with Kedrion

Published Wed, Dec 6 2023 12:00 PM UTC



Kamada Ltd., a renowned global biopharmaceutical company specializing in rare and serious conditions, has recently signed a game-changing agreement with Kedrion, a key player in the field of specialty plasma-derived products. The collaboration aims to enhance the distribution of KEDRAB, Kamada s innovative pharmaceutical product, in the United States. With this par...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 23.51
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 2.66
Price to Sales (Expected) -
Price to Book 1.78
PEG (TTM) 0.68

Financial Strength Current
Quick Ratio 1.07
Working Capital Ratio 2.73
Leverage Ratio (MRQ) 0.38
Total Debt to Equity 0.15
Interest Coverage (TTM) -
Debt Coverage (TTM) 1.04

Per Share Current
Earnings (TTM) 0.35 $
Revenues (TTM) 3.09 $
Cash Flow (TTM) -
Cash 1.29 $
Book Value 4.61 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 459,186
Net Income per Employee (TTM) 51,394
Receivable Turnover Ratio (TTM) 6.18
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.48

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) 58.72 %
Net Margin (MRQ) 7.97 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 12.72 %

Management Effectiveness Current
Return On Assets (TTM) 5.39 %
Return On Investment (TTM) 6.89 %
Return On Equity (TTM) 7.72 %
Dividend Yield -
Pay out Ratio (TTM) -



Kamada Ltd's Segments
Customer A    29.73 % of total Revenue
U S A    55.22 % of total Revenue
Israel    16.38 % of total Revenue
Latin America    13.42 % of total Revenue
Canada    5.99 % of total Revenue
Europe    5.24 % of total Revenue
Asia    3.72 % of total Revenue
Others    0.03 % of total Revenue
Proprietary Products    86.56 % of total Revenue
Distribution    13.44 % of total Revenue
segments    100 % of total Revenue

  Kamada Ltd Outlook

On March 6 2024 the Kamada Ltd provided following guidance

Kamada Ltd., a global biopharmaceutical company, has reported strong financial results for both the fourth quarter and fiscal year of 2023. The company has shown significant growth in revenue and profitability, with double-digit increases expected for the full year of 2024.

Based on the latest estimates provided on March 6, 2024, Kamada Ltd. has demonstrated its success as a leader in the specialty plasma-derived field. The company's portfolio of marketed products for rare and serious conditions has contributed to its robust performance in the biopharmaceutical industry.

Kamada's presence in the market, both on the NASDAQ and TASE, reflects its status as a commercial stage company with a strong...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.